Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2022 Dec 17;21(3):604–616. doi: 10.1016/j.cgh.2022.12.008

Table 1:

Current blood and stool-based screening assays

Current CRC genetic & epigenetic screening tests Diagnostic Test Study design Sample size Number of years recruited Population Age Sensitivity for CRC Specificity for CRC Sensitivity for advanced adenomas
Blood-based screening assays
Epi proColon, ColoVantage mSEPT9 Prospective Study 7941 2 years asymptomatic ≥50 48.2% 91.5% 11.2%
Stool-based screening assays
Cologuard MT-sDNA Prospective Study 10,000 2 years Average risk individuals undergoing screening colonoscopy ≥50 92.3% 86.6% 42.4%